Burden of Disease and Drug Response for Patients With Rheumatoid Arthritis by Shared Epitope and Anticitrullinated Protein Antibody Status
Our results highlight important differences in disease burden by SE/ACPA status and suggest that ACPA status, rather than correlative SE status, may be the stronger predictor of abatacept response among individuals with RA.
Authors
- Kaleb D. Michaud (ORCID: https://orcid.org/0000-0002-5350-3934)
- Joshua F. Baker (ORCID: https://orcid.org/0000-0003-0799-7563)
- Keith Wittstock (ORCID: https://orcid.org/0000-0002-4080-1916)
- Kristin Wipfler (ORCID: https://orcid.org/0000-0001-8137-8117)
- Harlan R Sayles (ORCID: https://orcid.org/0000-0002-4082-8289)
- Ted R. Mikuls (ORCID: https://orcid.org/0000-0002-0897-2272)
- Sang Hee Park (ORCID: https://orcid.org/0000-0003-2545-2938)
Institutions
- Nebraska Medical Center (US)
- Bristol-Myers Squibb (United States) (US)
- The National Databank for Rheumatic Diseases (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Bristol-Myers Squibb (Japan) (JP)
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0445
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00